ࡱ>  gbjbj΀ K]((kkkkk44$Hb,#######$&Z)>$uk"$kkY$ Vkk# # c##=r{##$0$#,)n ^)#)k#0 $$ $)( 1: ATYPICAL CELIAC DISEASE: COULD YOU BE MISSING THIS COMMON PROBLEM? Consultant, Vol. 50, No. 3;  HYPERLINK "http://www.consultantlive.com/display/article/10162/1531922" www.consultantlive.com/display/article/10162/1531922 By MANOJ KUMAR, MD, MPH and GREGORY W. RUTECKI, MD University of South Alabama | March 3, 2010 Dr Kumar is a resident in internal medicine at the University of South Alabama College of Medicine in Mobile. Dr Rutecki is professor of medicine at the University of South Alabama. He is also a member of the editorial board of CONSULTANT. Dr Kumar and Dr Rutecki report that they have nothing to disclose.  ABSTRACT: For every recognized case of celiac disease, 8 more remain undiagnosed. The reason for this disparity is contingent on the varying presentations of the disease. What was once considered solely a GI disorder, uniformly presenting with diarrhea and malabsorption, has evolved into a multisystem autoimmune disorder with myriad symptoms and signs. In addition, celiac disease is no longer a disorder limited to childhood and adolescence; it has even been diagnosed for the first time in elderly patients. Atypical celiac disease can be found in patients who present primarily with hypothyroidism, liver enzyme elevations, Addison disease, type 1 diabetes mellitus, and other disorders with major pathology outside the GI tract. Studies have demonstrated that an active casefinding strategy in primary care practice can increase the diagnostic yield for celiac disease. If you were to ask other primary care practitioners which subspecialty niche celiac disease should occupy, most would probably respond, "Gastroenterology, of course." Until recently, we would have agreed. However, celiac disease or, better yet, celiac syndrome needs to be "reframed" for contemporary clinicians. For example, "atypical" celiac diseasewhich presents with few or even no GI symptoms or signsis largely responsible for the increased prevalence of celiac disease today.1 Extraintestinal manifestations of celiac disease are rapidly becoming the rule rather than the exception. One example is thyroid disease, which occurs 4.4 times more frequently in patients with celiac disease than it does in control populations.2 In some of these persons, the thyroid disorder may be diagnosed and treated appropriately, but celiac disease may be either overlooked or only diagnosed later. Celiac disease can be associated with a variety of autoimmune diseases including type 1 diabetes mellitus, autoimmune liver disease, Graves disease, and Addison disease.3 Thus, celiac disease has become one of our generation's great "masqueraders," similar to the role syphilis played in William Osler's day. Because of the myriad and frequently enigmatic presentations of celiac disease, the challenge of diagnosis falls squarely on the shoulders of primary care practitioners. Most cases are currently undiagnosed; however, one study demonstrated that an active case-finding strategy in primary care practices improves the detection rate.3 The study included 737 women and 239 men older than 40 years. Any participant with a family history of celiac disease or unexplained anemia or iron deficiency, recurrent abdominal pain or bloating, irritable bowel syndrome (IBS), chronic fatigue, unexplained liver enzyme abnormalities, or an autoimmune disease was offered serological screening for celiac disease. Those with a positive result were referred to a gastroenterologist for duodenal biopsy. The result of this approach was a 32- to 43-fold increase in the case finding of celiac disease.3 This study demonstrated that reframing celiac disease as a systemic autoimmune disorder is the key to earlier diagnosis. Here we will discuss how this approach can be used in primary care practice to augment case finding and appropriate consultation. We will present 3 case studies that illustrate atypical presentations of the disease, and we will also describe high-yield screening studies. The average delay in the diagnosis of celiac disease may be as long as 13 years.4 Moreover, for every recognized case, 8 more remain undiagnosed.4 Clearly, the current approach to celiac disease is in need of an update. Broadening the definition. Celiac disease is no longer considered a disease limited to childhood or adolescence. It can present in any age group and has even been diagnosed for the first time in elderly patients ( HYPERLINK "http://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=2" \l "case1" Case 1). Case 1 Older Woman With Refractory Iron Deficiency Anemia CLINICAL BACKGROUND You evaluate a 76-year-old woman for the first time at a local nursing home. Her medical history includes iron deficiency anemia, osteopenia, and hypothyroidism. Her only surgery was a hysterectomy for uterine fibroids 30 years earlier. She takes iron supplements, a bisphosphonate, and thyroid hormone replacement therapy. She feels generally well, although she reports fatigue and decreased energy. Her weight has been stable, and she is active in her nursing home community. A review of systems is otherwise negative, and physical findings are unremarkable. A previous workup for iron deficiency revealed no GI source of bleeding. Multiple fecal occult blood tests were negative, and the results of 2 colonoscopies and upper endoscopies were normal. There are no other apparent sources of blood loss; she had a hysterectomy years earlier, and her urine has never contained gross or microscopic blood. Despite the patient's adherence to the iron replacement regimen, laboratory values continue to be abnormal (hemoglobin, 10.4 g/dL; red blood cell distribution width, 20%; mean corpuscular volume, 70 m3; and ferritin, 20 ng/mL). You suspect that iron deficiency is limiting her quality of life. How would you proceed? CASE DISCUSSION The duodenum is the anatomical site where iron is absorbed from the GI tract. This patient's primary care physician ordered initial serological screening tests for IgA antitissue-transglutaminase and IgA anti-endomysial antibodies, which were positive. An endoscopy with 6 separate duodenal biopsies confirmed celiac disease. A gluten-free diet was prescribed. The patient's ferritin level increased, and the anemia and microcytosis resolved. She also reported increased energy. It was suspected that celiac disease might have contributed to her osteopenia and hypothyroidism as well. TAKE-HOME MESSAGE The prevalence of celiac disease is increasing among elderly patients.44 In fact, 25% of patients in one study received a diagnosis of celiac disease in their seventh decade.45 Consider atypical celiac disease in elderly patients with unexplained anemia, osteopenia, or endocrine disease. Such patients may lack classic GI malabsorptive symptoms and signs. Elderly persons with celiac disease may have low folic acid and vitamin B12 levels or a calcium deficiency from occult intestinal malabsorptive abnormalities.44 Like their younger counterparts, elderly persons with celiac disease may present with dermatitis herpetiformis ( HYPERLINK "http://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=2" \l "figure2" Figure 2). In some older adults, biopsy-proven collagenous colitis may suggest celiac disease.46 In a cohort of patients with celiac disease who also had dementia, a gluten-free diet improved cognitive deficiency.47 Keep in mind that the gluten filler in medication capsules may cause relapse in some treated patients.44 Since Samuel Gee's 1887 description of diarrhea as the only classic symptom of celiac disease,5 diarrhea has been accepted as a "universal symptom." If a patient did not have diarrhea, the physician did not think of celiac disease. This era's challenge is to realize that celiac disease frequently presents without diarrhea. Today, the disease is a broader syndrome without a single or universal symptom; instead, it manifests itself as a systemic illness in organs outside the GI tract. This phenomenon is evidenced by the robust attention paid to extraintestinal celiac disease in recent literature.6-8 Before 1980, about 71% of patients in whom celiac disease was diagnosed had diarrhea. More recently, the incidence of diarrhea as a manifestation of the disease has dropped to 37%.9 Updated classification. Celiac disease can be classified as typical (classic or symptomatic with intestinal symptoms and signs), atypical (with extraintestinal or atypical symptoms and signs), or silent/latent (completely asymptomatic and, as a result, undiagnosed). This classification represents an updated diagnostic paradigm for the disease. Symptoms of typical celiac disease include abdominal pain, often crampy in nature and associated with distention; dyspepsia and other symptoms of gastroesophageal reflux disease; and altered bowel habits accompanied by diarrhea. Patients with typical celiac disease frequently experience weight loss, anemia (from iron or vitamin B12 deficiency), and fatigue, and they can have osteopenia.7 A newer observation regarding typical celiac disease is that it can mimic IBS. A study showed that of 105 patients presumed to have IBS, 11.4% actually had celiac disease. After appropriate diagnostic studies, these patients were treated for celiac disease, rather than for IBS, and their symptoms abated.10 Another British study evaluated about 300 patients with IBS and found 22% of them had specific antibodies that suggested celiac disease. Later, 4.7% of these patients were unequivocally confirmed to have celiac disease by intestinal biopsies.11 Atypical celiac disease is characterized by the absence of "typical" GI manifestations. Patients present with signs previously considered secondary or unusual accompaniments of celiac disease, such as iron deficiency or elevated liver enzyme levels ( HYPERLINK "http://www.consultantlive.com/display/article/10162/1531922?pageNumber=2" \l "case1" Case 1 and  HYPERLINK "http://www.consultantlive.com/display/article/10162/1531922?pageNumber=3" \l "case2" Case 2). Case 2 Adolescent With Unexplained Liver Enzyme Abnormalities CLINICAL BACKGROUND A 16-year-old girl comes to your office because of persistent, mild liver enzyme elevations. On 2 occasions during the past 6 months, she has had aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of 80 U/L and 92 U/L and 94 U/L and 90 U/L, respectively. She is otherwise healthy except for seasonal allergies. She takes no medications (either over-the- counter or prescription), does not use any alternative therapies, and does not drink alcohol or use illicit drugs. She does not recall ever having jaundice or hepatitis. There is no significant past medical or family history. She is an athlete and is not obese (body mass index, 21). Physical findings are normal for her age. Additional laboratory testing reveals the following values: normal complete blood cell count, continued similar elevations of AST and ALT, and normal metabolic parameters (including glucose and triglycerides). Other liver-related studiesalbumin, total protein, bilirubin, and alkaline phosphatase levelsare normal. An ultrasound examination demonstrates a normal liver without suggestion of steatosis. A second set of laboratory studies is ordered to further investigate the persistent elevations in AST and ALT. Viral causes are excluded by normal results for hepatitis A, B, and C panels; as well as measurement of Epstein-Barr virus and cytomegalovirus antibody levels. The ceruloplasmin level is also normal. An autoimmune liver disease panel (antinuclear antibody and anti kidney/liver microsome, anti liver cytosol, and anti smooth muscle antibodies) is negative. Evaluation for 1-antitrypsin deficiency is also negative. Would you test this patient for celiac disease? CASE DISCUSSION She should definitely undergo serological testing (antitissue-transglutaminase and anti-endomysial antibodies) for latent or atypical celiac disease. The most common hepatic presentation of celiac disease is an isolated elevation of AST and ALT (typically less than 5 times the upper limit of normal values).48 In fact, after workup for unexplained liver enzyme elevations, about 1 in 10 persons are found to have celiac disease.49 TAKE-HOME MESSAGE Celiac disease is also associated with more severe liver disease, including an 8-fold increase in the risk of cirrhosis.49 The clinical connection between celiac disease and primary biliary cirrhosis may be related to a common immunological mechanism.49 Other studies have demonstrated a relationship between celiac disease and autoimmune hepatitis and primary sclerosing cholangitis. Consensus guidelines strongly recommend that serological tests for celiac disease be included in the comprehensive screening of persons with liver enzyme elevations.50 It is the autoimmune characteristics of celiac disease that make it a multisystem disorder. The antibodies associated with celiac disease target multiple organs outside the GI tract;  HYPERLINK "http://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=4" \l "table1" Table 1 highlights the various organ systems that can be involved.6,7  HYPERLINK "http://www.consultantlive.com/display/article/10162/1531922?pageNumber=4" \l "case3" Case 3 illustrates a subtle presentation of atypical celiac disease in primary care practice. Silent celiac disease occurs in persons who are asymptomatic but who have a positive serological test and villous atrophy on biopsythe classic pathology of celiac disease ( HYPERLINK "http://www.consultantlive.com/display/article/10162/1531922?pageNumber=1" \l "figure1" Figure 1). Testing is performed because the patient has relatives with celiac disease. Case 3 Man With Type 1 Diabetes Mellitus and Addison Disease CLINICAL BACKGROUND A man in his 30s presented to the emergency department (ED) with hypotension (95/60 mm Hg). He had a 10-year history of type 1 diabetes mellitus, and his most recent hemoglobin A1c (HbA1c) level was 7.4%. Infection and sepsis were initially suspected, but the serum sodium and potassium levels were 110 mEq/L and 7.0 mEq/L, respectively. The ED physician noted that the patient was "pigmented." The combination of hypotension and hyperpigmentation in a patient with type 1 diabetes mellitus accompanied by characteristic electrolyte abnormalities suggested an underlying autoimmune syndrome manifested by Addison disease. The patient was treated vigorously with normal saline as well as parenteral and later oral corticosteroids, and his condition improved. A random serum cortisol concentration was 1 g/dL and increased to 3 g/dL only after stimulation with parenteral adrenocorticotropic hormone (ACTH). The patient continued to do well with insulin and oral prednisone. Many years later, he comes to you with well-controlled type 1 diabetes mellitus (HbA1c, 6.9%) and Addison disease that has not caused further problems. He is found to have iron deficiency (hemoglobin level, 11.0 g/dL; red blood cell distribution width, 18%; mean corpuscular volume, 69 m3; and ferritin level, 15 ng/mL). The patient has no GI complaints, and 3 fecal occult blood tests are negative. His thyroid-stimulating hormone level is high, consistent with hypothyroidism. Tests for antithyroid antibodies are positive. How would you proceed? CASE DISCUSSION Celiac disease is an autoimmune disorder. Affected patients produce highly disease-specific IgA and IgG autoantibodies to tissue transglutaminase. Their own lymphocytes can be cytotoxic to intestinal and many other cells in the body.51 The prevalence of celiac disease is higher among persons with type 1 diabetes mellitus (5.7%), also an autoimmune disease, as well as among relatives of those with type 1 diabetes (1.9%), compared with age-matched controls.52 More recent data have demonstrated that persons with type 1 diabetes mellitus and those with celiac disease share a common genetic background.53 In fact, the 2 diseases share 7 genetic regions. This patient's antibody screening tests were positive for celiac disease, and he was referred to a gastroenterologist. TAKE-HOME MESSAGE Consider celiac disease as an underlying pathology in patients with autoimmune endocrine diseases, such as type 1 diabetes mellitus, hypothyroidism, and Addison disease, whether or not diarrhea is present. Latent celiac disease is defined by a normal duodenal biopsy result in a person with a positive serology and family history who is consuming a regular (gluten-containing) diet. Villous atrophy develops in such persons later in life. Although many persons with latent celiac disease are asymptomatic, some have symptoms and therefore may present in the primary care setting.12 PATHOGENESIS OF CELIAC DISEASE Role of heredity. HLA complex class II genes are involved in the pathogenesis of celiac disease.13 Louka and Sollid14 have implicated the inheritance of HLA-DQA1*05- DQB1*02 (DQ2) and DQA1*03- DQB1*0302 (DQ8) as a predisposition to the development of celiac disease. International twin studies have also demonstrated that there is a 70% to 85% concordance rate of celiac disease in monozygotic twins and a 10% to 20% rate in dizygotic twins.15,16 HLA genes contribute approximately 53% to the total prevalence of celiac disease.17 Thus, the disease does not develop in all persons who have "at-risk" HLA genes; the role of non-HLA genes is also vital to its pathogenesis. Currently, the non- HLA genes that are potentially associated with celiac disease include COELIAC2 (5q31-33), COELIAC3 (2q33), and COELIAC4 (19p13.1).18-20 The 11q locus also has been documented to confer some degree of susceptibility to the eventual development of the disease.21 Environmental triggers. The role of environmental factors is as important as a genetic predisposition to celiac disease. The putative role of a gluten-rich diet is well known. Gluten is the storage portion of wheat protein. It has 2 major components: gliadins and glutenins. Other proteins associated with celiac disease may be found in barley (hordeins) and rye (scalins). Oats are not typically implicated as a trigger for celiac disease. Of all the potential triggers for celiac disease, glutenins have the strongest association.22-24 Kagnoff25 detailed the following series of events as a plausible environmental pathogenesis for celiac disease. When a genetically predisposed person (who has HLA and/or other candidate genes) ingests a gluten-rich diet, the proline content of gluten resists complete digestion. As a result, it accumulates within undigested gluten peptides. These undigested peptides cross the intestinal epithelial barrier and reach the lamina propria. There they come in contact with tissue transglutaminase (t-TGase) and antigen-presenting cells (APCs). APCs express HLA-DQ2 or HLADQ8 heterodimers, which have the capacity to bind to t-TGase. Once this binding occurs, APCs present the bound combination to CD4+ T cells specific for HLA-DQ2 and HLA-DQ8. These T cells release inflammatory mediators and cause villous injury.25 Possible mechanism for extraintestinal manifestations. Tissue-TGase assists in cell-matrix interactions and thus plays a vital role in building extracellular matrix. This enzyme is present in nearly every organ throughout the body; it is not limited to the GI tract.26,27 Tissue-TGase gluten residues may produce generalized antigenic epitopes through cross-linking undigested gliadin peptides.22 These peptides then cross intestinal barriers, reaching the lamina propria. There the complexes undergo endocytosis, further processed by specific B cells. These B cells present the complexes to gliadin-specific T cells, triggering immune reactions against t-TGase.28,29 The autoantibodies are known as antitissue-transglutaminase (antit-TGase) antibodies. Since t-TGase is ubiquitous, these antibodies have the potential to injure multiple organs through inflammatory reactions. SCREENING FOR CELIAC DISEASE IN PRIMARY CARE PRACTICE   HYPERLINK "http://www.consultantlive.com/image/image_gallery?img_id=1531757&t=1267644981866"  Older diagnostic criteria. The European Society of Pediatrics, Gastroenterology, and Nutrition (ESPGAN) published diagnostic criteria for celiac disease in 197030,31 and modified them in 1990 ( HYPERLINK "http://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=6" \l "table2" Table 2).31,32 The criteria initially focused on celiac disease as a GI disorder and were also intended primarily for children. A new diagnostic approach. Serological tests have become essential to the diagnosis of celiac disease. The arrays available in the primary care setting have included IgA antigliadin antibody, IgA antireticulin, IgA antiendomysial antibody (EMA) and, more recently, antit-TGase antibody. 33-38 IgA antigliadin antibody was the earliest screening choice. Screening for IgA antit-TGase antibodies, coupled with EMA, confers sensitivities of 98% to 100%, specificities of 98% to 100%, a positive predictive value of 90%, and a negative predictive value of 95% for celiac disease.4 The current American Gastroenterological Association guidelines support the use of IgA antit-TGase antibody and not EMA as a screening test for celiac disease.39 EMA is a confirmative test and should not be used for screening because of its lower sensitivity. Antireticulin is not recommended as a screening test. Who should be screened? In addition to patients with typical GI manifestations, anyone who has a potential atypical presentation of celiac disease can benefit, such as patients with unexplained endocrine autoimmunity or IBS. Also consider screening for latent disease in persons who have a positive family history. Refer patients with positive antibody screening results for endoscopy and duodenal biopsy. An experienced laboratory is required for diagnostic accuracy. Certain variables may contribute to the predictive power of tD^`a w x y z  CDcʻ⮣yi^^^^^^^؈hFH*OJQJ^JhLhF0J5OJQJ^JhR*hF0JOJQJ^JhF0JOJQJ^Jjh<hFOJQJUh<hFOJQJhLhFOJQJ^JhfMhF0JOJQJ^JjhFOJQJU^JhFOJQJ^JhFhFOJQJ^J hLhFCJOJQJ^JaJ"DC w y z h!(<r  d-D`M gdF dgdF hdgdFdgdF hd^hgdFgdFcd&(;.0  q""""7#9#<$>$$$%%%%%%%%_&a&&&/'0'/)2))))*U+k+,,,,.....ѴѩѴѴѩѩўѩѩѩѩѩѩѩѴюўѩѩѩhLhF0J5OJQJ^JhFH*OJQJ^JhFH*OJQJ^JhF0JOJQJ^J hF5CJ$OJQJ\^JaJ$hFOJQJ^J hF0JhF5OJQJ\^J!jhF5OJQJU\^J6 i!q"r"":##%&&'))D+,.0001013dd-D`M [$gdF hd`hgdFdgdFd-D`M gdF.////_0`0f0g0l0m00000011/18899!;#;;;;;-</<<<==>>??!?"?]?`?a?b?????+@ɼɶɼɶڥڙڎڙڃڃڙڃڃڃɼɶڃɼɶhFH*OJQJ^JhFH*OJQJ^JhF0JOJQJ^J hF5CJ$OJQJ\^JaJ$ hF0JhF5OJQJ\^J!jhF5OJQJU\^JhFOJQJ^JhLhF0J5OJQJ^JhF0JOJQJ^J135999;;;==AAAAzC|GJJJKNNN -D`M gdF hgdF$a$gdFd-D`M gdFhd-D`M `hgdF+@@@@@FcC[=WX>1vm ,S_]m %eoqVWY3 :nЯ}V(6Cr+v+AսoY,>[6Z1ۜ7c1ءȬYYtuRz,vS!XoCuWo( ݏN>u-o#gK?MgK(WQ[}ce6zn2벿ҷ}vK,[pc_[KvQ]MW%mk+ cl}55=OkU[gi} cinßnʴ?/#o?G4bNJiVj8 Ӗm$2F66?3n'e-{UZ]s]͍Y{،ݍV+ɦʁ^]z*=f?b f kֵ69vk}oj61tl/;vո[?I*-zϲ"R89wksk=SJrK^O{oM|48[oDd,8Zmo~hXT52 nDzgmj/@ؗӓݎXsXw[ұܪՑ~žJ˜j׏k,{Gޭͫ`ٯ ѺWOac6c]]~*D ObUH>&?_A/tlGI =A:k g` 1hQiUX2+ ?/ ވ&ƨ!4; ؔX-Emn{v\vX:zΓlws=W [پָzͰ2E]ƽV }k~=|\I`v[=FWo_w_cʠӰWwֺeWˌDce}O?Wzp ?~k}Wj6`.fY`0=:`DZsm?U9]vYl0MEb+ƫmӻGn%aV~ߣ7@oO\Ue'X! v>R̭{]}_~O_f-}OLFYeos9TſKNVڟE?T ҪA9ι{vZ팲n3翜1?xrܛ+S\80z1=Z_Rʨ^=ڭ{ ҩ\Ud}bг$pkZܫO- Xqq]cFmGk}F;=?7^NE?T ҫC j78ꇼϥ(a1]uyup[ӜZ1}>}׻Kx7(*oQu?UXB^JI&֖1k]ߣMPl:V\nkii=۲ֳc+>V?E?T Ҫ_.7qE'_n-cԕG?Vr\ٺ;sZ]Vǡ^/oQu?U/ߒ.?wx7(*W]K6zKsnMo~~,[RP3/w{z6;~*׻Bbcz][L67{򭲧Z3}޺XÀ솇MV9/Fs21v#qeNZЯղ] OLeUٶuowszv@fwla9UC^ﭵ3mo?;:9Pּŧhc=/Uܚξ[1v w46;f}-eY"mO9.%Տ5v}ދ]mul[ī)N]h5! 8ZZ+{[}-=E :_ȱ^&㧵c}/潞 s?sI&_c^ZA>Z[c~Ƿ. =?n_kJ?m-Jfuemƥ~naMֵw;?JM_ŷi.F>u 96?QX6cdXXƹ6:0Iޗ=f%7scK8.}nooJn/2A;}1'pclw;\_ӝXc7Rwgk{?Kooc7e?&^19xsGJO{GmeVd]Ųu ;w vn/kȫ)6GT?gr/[A߫nݮW}j?Y9-nU,ýe{Sg=;ZQ/)͝aTߥKzhvrbL2=g߻evl??M-CE `ipo{H\nk[һEeؕ}G[qn45kZe^Wsɧg+":}S[it8>6o@uVzf@][{ջo3WK?Eb9}Z܆ӗqen2A[ߥY;^[]9's]2"޹ysXzV[^@.;egk *uRPYU3Ҳ$s;n;> RoG@ ŽnSF8ıd}M{+.۹`ulN0";Üꩱ^Y~oMu-oj/7zF;me;7+?ѥiލtLcm{9qmW_N9goM1ŭk纪m[{=[*g?GYmHk6K}ZwձZ}_G_tX-s\]g潬{=621޳OO)mlp 9wЮm_zsz_bn5==9}zNZX]rm9ʩilwk}o}(q[k8Uh{^7ִ==f*E_X^;iu"}HkNB?e_K_70ʫʻ׼-.{ݍVlj4p͉mٷw ;+ L_nEg3= U_2.S2-hp$=/Uk?J#ԓ┟-Xrߊ2Idݵ]?K1#Uk:ൎ ;w߫=v}/NGJUnJAp{C}ݷowoZXqf5MeaEI,3BRIJ{VT}iL ;۫_TþzCV8ټSϷG׈S'<ym5cFj={w3w~OW Om,ǫԦ[-1Iۙ]Ucvz)WE,u2qEx sl{_Teonz7Pv06n -plO%^)u3/w{zzoŸs5ΰ=lTʿuh~_=.wJƲk_ZcVg1Wb:L],w=[ճs_OH333ed`yNʚY]v"~Ʒ\F!XR]i?M*ditjf?AϬP{mo_lr.ON&}ִA`MOwuowUmϥUvQWYW#{=Gޠ[R`@kqtvm'ҿ4I抪5f8%}[WmխI+׹s,;g^8T\3kl0]%mNu{_{tꡎN-YԷ[kZ*k`6!z~SE `-c}MzR:>.QHsS]uޭVQγor}}n՝mVSU='Sm [6ײm_Om뭗׻c44}oW⦐-u7*SC"u羆[?=gHW`;%c?[Mf?}зۏ(kάu.Hzz_Sں ^vs-+SZU6WK &`moڬy? kHMuֵ۳};l؊NqreleAml~vR_YpͯzU'V/kRyi$S{n{,I稓zg]h1\DKX`okC^=e?j_%?OBnѹA{r[(}U'/Ypͯz?OR)?OBUγ-{C?vWv?OP:\:~\?Aw# b!hħi9>fnٙwٳ=5_WJT:x}WJ_kpKzW?j__җ??Rޕ%ھwaԿxIi]X~)}/^*Zx*}WJ_kpKzW?j__җ??Rޕ%ھwaԿxIi]X~)}/^*Zx*}WJ9Ӊvr}0;=SvOzRKO?:Photoshop 3.08BIM%8BIMHH8BIM&?8BIM x8BIM8BIM 8BIM 8BIM' 8BIMH/fflff/ff2Z5-8BIMp8BIM8BIM8BIM08BIM-8BIM@@8BIM8BIMIs Untitled-4snullboundsObjcRct1Top longLeftlongBtomlongRghtlongsslicesVlLsObjcslicesliceIDlonggroupIDlongoriginenum ESliceOrigin autoGeneratedTypeenum ESliceTypeImg boundsObjcRct1Top longLeftlongBtomlongRghtlongsurlTEXTnullTEXTMsgeTEXTaltTagTEXTcellTextIsHTMLboolcellTextTEXT horzAlignenumESliceHorzAligndefault vertAlignenumESliceVertAligndefault bgColorTypeenumESliceBGColorTypeNone topOutsetlong leftOutsetlong bottomOutsetlong rightOutsetlong8BIM( ?8BIM8BIM CV@'JFIFHH Adobe_CMAdobed            V" ?   3!1AQa"q2B#$Rb34rC%Scs5&DTdE£t6UeuF'Vfv7GWgw5!1AQaq"2B#R3$brCScs4%&5DTdEU6teuFVfv'7GWgw ?kӃFmTPnehHk[Uorgmm Z/X׍P9WC[w}XSR)nqġ ťfCg[Og=gG#}Ee 6l mo"sX:N}*CW{jʾCk,s2XG3Lr5ې^=vNgTZY-źu~cǦ̪qi.>FcC[=WX>1vm ,S_]m %eoqVWY3 :nЯ}V(6Cr+v+AսoY,>[6Z1ۜ7c1ءȬYYtuRz,vS!XoCuWo( ݏN>u-o#gK?MgK(WQ[}ce6zn2벿ҷ}vK,[pc_[KvQ]MW%mk+ cl}55=OkU[gi} cinßnʴ?/#o?G4bNJiVj8 Ӗm$2F66?3n'e-{UZ]s]͍Y{،ݍV+ɦʁ^]z*=f?b f kֵ69vk}oj61tl/;vո[?I*-zϲ"R89wksk=SJrK^O{oM|48[oDd,8Zmo~hXT52 nDzgmj/@ؗӓݎXsXw[ұܪՑ~žJ˜j׏k,{Gޭͫ`ٯ ѺWOac6c]]~*D ObUH>&?_A/tlGI =A:k g` 1hQiUX2+ ?/ ވ&ƨ!4; ؔX-Emn{v\vX:zΓlws=W [پָzͰ2E]ƽV }k~=|\I`v[=FWo_w_cʠӰWwֺeWˌDce}O?Wzp ?~k}Wj6`.fY`0=:`DZsm?U9]vYl0MEb+ƫmӻGn%aV~ߣ7@oO\Ue'X! v>R̭{]}_~O_f-}OLFYeos9TſKNVڟE?T ҪA9ι{vZ팲n3翜1?xrܛ+S\80z1=Z_Rʨ^=ڭ{ ҩ\Ud}bг$pkZܫO- Xqq]cFmGk}F;=?7^NE?T ҫC j78ꇼϥ(a1]uyup[ӜZ1}>}׻Kx7(*oQu?UXB^JI&֖1k]ߣMPl:V\nkii=۲ֳc+>V?E?T Ҫ_.7qE'_n-cԕG?Vr\ٺ;sZ]Vǡ^/oQu?U/ߒ.?wx7(*W]K6zKsnMo~~,[RP3/w{z6;~*׻Bbcz][L67{򭲧Z3}޺XÀ솇MV9/Fs21v#qeNZЯղ] OLeUٶuowszv@fwla9UC^ﭵ3mo?;:9Pּŧhc=/Uܚξ[1v w46;f}-eY"mO9.%Տ5v}ދ]mul[ī)N]h5! 8ZZ+{[}-=E :_ȱ^&㧵c}/潞 s?sI&_c^ZA>Z[c~Ƿ. =?n_kJ?m-Jfuemƥ~naMֵw;?JM_ŷi.F>u 96?QX6cdXXƹ6:0Iޗ=f%7scK8.}nooJn/2A;}1'pclw;\_ӝXc7Rwgk{?Kooc7e?&^19xsGJO{GmeVd]Ųu ;w vn/kȫ)6GT?gr/[A߫nݮW}j?Y9-nU,ýe{Sg=;ZQ/)͝aTߥKzhvrbL2=g߻evl??M-CE `ipo{H\nk[һEeؕ}G[qn45kZe^Wsɧg+":}S[it8>6o@uVzf@][{ջo3WK?Eb9}Z܆ӗqen2A[ߥY;^[]9's]2"޹ysXzV[^@.;egk *uRPYU3Ҳ$s;n;> RoG@ ŽnSF8ıd}M{+.۹`ulN0";Üꩱ^Y~oMu-oj/7zF;me;7+?ѥiލtLcm{9qmW_N9goM1ŭk纪m[{=[*g?GYmHk6K}ZwձZ}_G_tX-s\]g潬{=621޳OO)mlp 9wЮm_zsz_bn5==9}zNZX]rm9ʩilwk}o}(q[k8Uh{^7ִ==f*E_X^;iu"}HkNB?e_K_70ʫʻ׼-.{ݍVlj4p͉mٷw ;+ L_nEg3= U_2.S2-hp$=/Uk?J#ԓ┟-Xrߊ2Idݵ]?K1#Uk:ൎ ;w߫=v}/NGJUnJAp{C}ݷowoZXqf5MeaEI,3BRIJ{VT}iL ;۫_TþzCV8ټSϷG׈S'<ym5cFj={w3w~OW Om,ǫԦ[-1Iۙ]Ucvz)WE,u2qEx sl{_Teonz7Pv06n -plO%^)u3/w{zzoŸs5ΰ=lTʿuh~_=.wJƲk_ZcVg1Wb:L],w=[ճs_OH333ed`yNʚY]v"~Ʒ\F!XR]i?M*ditjf?AϬP{mo_lr.ON&}ִA`MOwuowUmϥUvQWYW#{=Gޠ[R`@kqtvm'ҿ4I抪5f8%}[WmխI+׹s,;g^8T\3kl0]%mNu{_{tꡎN-YԷ[kZ*k`6!z~SE `-c}MzR:>.QHsS]uޭVQγor}}n՝mVSU='Sm [6ײm_Om뭗׻c44}oW⦐-u7*SC"u羆[?=gHW`;%c?[Mf?}зۏ(kάu.Hzz_Sں ^vs-+SZU6WK &`moڬy? kHMuֵ۳};l؊NqreleAml~vR_YpͯzU'V/kRyi$S{n{,I稓zg]h1\DKX`okC^=e?j_%?OBnѹA{r[(}U'/Ypͯz?OR)?OBUγ-{C?vWv?OP:\:~\?Aw# b!hħi9>fnٙwٳ=5_WJT:x}WJ_kpKzW?j__җ??Rޕ%ھwaԿxIi]X~)}/^*Zx*}WJ_kpKzW?j__җ??Rޕ%ھwaԿxIi]X~)}/^*Zx*}WJ9Ӊvr}0;=SvOzRKO?8BIM!UAdobe PhotoshopAdobe Photoshop CS38BIMhttp://ns.adobe.com/xap/1.0/ XICC_PROFILE HLinomntrRGB XYZ  1acspMSFTIEC sRGB-HP cprtP3desclwtptbkptrXYZgXYZ,bXYZ@dmndTpdmddvuedLview$lumimeas $tech0 rTRC< gTRC< bTRC< textCopyright (c) 1998 Hewlett-Packard CompanydescsRGB IEC61966-2.1sRGB IEC61966-2.1XYZ QXYZ XYZ o8XYZ bXYZ $descIEC http://www.iec.chIEC http://www.iec.chdesc.IEC 61966-2.1 Default RGB colour space - sRGB.IEC 61966-2.1 Default RGB colour space - sRGBdesc,Reference Viewing Condition in IEC61966-2.1,Reference Viewing Condition in IEC61966-2.1view_. \XYZ L VPWmeassig CRT curv #(-27;@EJOTY^chmrw| %+28>ELRY`gnu| &/8AKT]gqz !-8COZfr~ -;HUcq~ +:IXgw'7HYj{+=Oat 2FZn  % : O d y  ' = T j " 9 Q i  * C \ u & @ Z t .Id %A^z &Ca~1Om&Ed#Cc'Ij4Vx&IlAe@e Ek*Qw;c*R{Gp@j>i  A l !!H!u!!!"'"U"""# #8#f###$$M$|$$% %8%h%%%&'&W&&&''I'z''( (?(q(())8)k))**5*h**++6+i++,,9,n,,- -A-v--..L.../$/Z///050l0011J1112*2c223 3F3334+4e4455M555676r667$7`7788P8899B999:6:t::;-;k;;<' >`>>?!?a??@#@d@@A)AjAAB0BrBBC:C}CDDGDDEEUEEF"FgFFG5G{GHHKHHIIcIIJ7J}JK KSKKL*LrLMMJMMN%NnNOOIOOP'PqPQQPQQR1R|RSS_SSTBTTU(UuUVV\VVWDWWX/X}XYYiYZZVZZ[E[[\5\\]']x]^^l^__a_``W``aOaabIbbcCccd@dde=eef=ffg=ggh?hhiCiijHjjkOkklWlmm`mnnknooxop+ppq:qqrKrss]sttptu(uuv>vvwVwxxnxy*yyzFz{{c{|!||}A}~~b~#G k͂0WGrׇ;iΉ3dʋ0cʍ1fΏ6n֑?zM _ɖ4 uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)KmAdobed         s/  s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjzm!1AQa"q2#BRbr3$4CS%cs5DT &6E'dtU7()󄔤euFVfvGWgw8HXhx9IYiy*:JZjz ?D'|뛟/iOY4Yۻ333!,MY`Nf@W,?m4dx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴*'mx޴73C}Vky3\E?BEsJ{&*ijxQ_='ޟavrY+`HI#uFI':l>ʾ1 Oоiօ?d>Gȍ^=KoNRp#?S<[ݓdR<_*qiڛ\=FxmN Ƿ&Y82 eH"2AJU\Ԯhkg}\@VDY#Bd"q˖D|Qć1薚i]Kd_K#8^qʥ}"r8FH7<[עk-Ҏ~/pxFrjEeNChᐢ3_x_/jp8$q2Xx~N0Or ev*UثWb]v*UY_쟗/lLO.@mSlu֏Fm:O;5奺I6&BD^?_79k$6I'&Ml5"Y[mhM$|VO_Qd; Gy?_[ʷWWÌRe)(Փ@,^`N=zPwz(n־s7.rzP$a!@wtw6z5]{RӬYZ'+ﵓåkooc=rn>a!W(ܾ[m6hwEg"Cor8ȃRyD󥶭k߶EGMXb9oJ@},g%yKo+n`mb̑-{  |dGlE>^V\}2X6EG?ߑzH# ɲw{$c7~\}ʺnj:7ZͽH!Xc[9C²KC3dģg(ouEԴWXTeev+DPxO^ÏO-7>Xe5sIzCW@@ pY>ʳbEK6ܶkiiM_Sx( H_ٷtj)_GեK-CD]gMEGqJs_g&=;gk!QO6Q5hVeH[.m(ԏc1JB6?3:ޥ eY *dP  kW6"M귮dB JNFyxz8_>=cB?(n,aK'X6q)ry昵F~:|>OyD:t7~=_QKBc!~QN~m5k{/_V[FIC3yF %C,w&!gΫ=+gzq<0H֡~>|Ō%!H݀y }ӄkagY]yj Y;{8 d Ѭr"|?[9D؀Y/B{ K{YlPݭ}Ybqq#n\Iy+W@aߚT]$i LdȪ2|m㑐H=Z֭2h#5OTtb1 蟵&@B)y_7itRVIW˷#[ 3}=եO'!D} WZ>ua_{1uVWu&I.MY#?`PM(-!Kݵ7qI$A$f+~~bH?:tkQдԲ4ue״"XZ#=[q\O:|ϫM_Ik( A9Dzz՛+/͗9iHثWb]v*UثWb>UrΟb쟗/lLO.@O/Vrz7sNAF(6F*UثWb]v*UثWb]v*mkW,o/Ch7}VAI@њGO wΣnt2i:̷QCq;dxx. ~_⋶<(*2 ZKu? SOjv_oi=公bff M&Vf?S t%ɏ; վ,u971RJg]tE~ rS.?-?<6mk6׉ᥞHF Uf #;'8C?,' Fv"75@[}g+zϛ;/r˟*(?)ZJ<,K'1Be)]Vom,qԍoMq1zG 4x2Ih2/L}> v#6w9 ;l6V*UثWb]v*UثWb]v*UثWb]v*UثWb]y65⫖t7쟗/lLO.@2)v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWb]v*UثWk_*gO߱~]/'=6j7>^;M4J4Ӄܓ_|O.?S5/xc]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K]*oj_K^O.~k>\z^ 9}?UQ`UY-uCԿ"Dec(?z2V^1;|-|Y嶭%vɥ-"ۛK$$3Ayr=XGեOqS0iHJ-M3Q) ''YkۈI_gxQ~BFk%Ԛ6Y\,RL?Mf俶sPHxh[d=:HևL/pRK&<$R 0\E-<@Zۇ/Ye17JRE@:yFVym~ }*6bIa+HMqek{s PQXDOR&WZ-o}u,(#=ԧF ?-ҧ>|1%j`-Zeq8X9^OV '6WӋVK-y~վ~'v6@ OZn?:$ɌzyVRZA>%ѡI`_6nQ\G/1TK&!y졚={ۀY41PN&KT5Y#Y x(+ʟ2+lRYAj۬rZތ~|_\?8# ZdG!,Z{qg5 Gi׏rdx94׵D#{7KvS]SapQ·f#:R[%?T&4Uf#ڔR=9ܗg~,>'ZFɺX];M@[⸳{T:pcW5_4ym[7,ax/GZ__洔]{ _C%eC/ dI#=?GyYmnO$no)[뺃}@Oi/u Ѥ5nP?rKqdih6&mejq vh\O?dA_1H_Z ln̳N#Ge/O?]Y4^yYnQulljKUݮ 4rz7Pyr'3sW-Oa-DpV7:zM/ f}ZKkMLjVUypz~I$-$|Zo܁0 ( r,N0+Wb]v*UثWk_*gO߱쟗/lLO.@2)Rչ FFp4Q;qUqWbW7VֶJ[BI""35T⪸Wb]v*UتwR]gOyn+5J_**UثWb]]YY=V$ m3aDRUXU%{-Tk$$3/UrğU]5ޥ\D/d̖Jѩ  4U!ul/jY =E*9_+~\UWv*UثWb]v*UثWk_*gO߱쟗/lLO.@qti՛vZH |#Uin"~YFi4_&i2ˢGm i3u[BepǑO߿'0DwlyѪ[irt\:kzbr/'Įj4ӇLinPl3HšŲ Wh7^jpo&!mξ`S3X ?Vw$#ddyDQM>/J*R1J:V`PÜK?i,;NgwyC]M1N\f GrzjÌ}QncD4o5,.-1[}jH_X7QxHLbϒiq5k_+'_W7#G&=fDli׳dDr_FiAJᲳ+x#w'HMU^2 ?a]¶Տ噊ύG5hb"rEWY~iļH{;yV<=m9Q۸iO&O1=F?klqty5~Ҵe7#}cyUaŕyy!RK t]wS#iɭOwfIL^[J4wnID^_{?2mUmK˹,o­—/ ԑZoFߺ~ GS?&Ӣ[{ DF $dni,N0zcOBb-6ɗTI59zm%[IH~)U⼱)ff[:1g{9&U'uo=xߒ1/%UrΟb쟗/lLO.@2)K-o[M?Xfӷ=I#q";G'IdVo_VF/>:}^JC3\;nVuYm*_gm6_Bg b*~ػ8,xҋSOqq&b\3[B^^jޣGtn_쿵ZL'hxRVH bUT|-9v_j}E6D0mIk`:[u7|p%Km \] xiT>bD,ѷ(2~+Ҝ=/IO=ZsO,Ivi,m-TZU?kHVƓ qeI }$z_Wʕ~w1I9LKHa"8-R0phz,/iѽƖΐƦ58&# Y~ce]6c:釗R^7KSHUtWg=4꘽%i^f^ *aNu}?Mu8GS% (?"UZLnIn! rK($)`HQI".JIh#}::1vn.eV\o˷Kivs2K,8Ib*SGr]|Lctxq43F7qn1DAo&;DK//%rvbE>֡ςR,yZ֑.%O$Envc1!2}( vGC4܋QpFN\%$գ7qvj&g"XcVҭZ^IDEeb%[yѕKXnO0 Z-7:w6gPiaJDܛ^",}AYgYxX𕴳Z󅝥Ɗ,m`.P]2[Ilc ֿFqe"PK bTOI +ԼH;ƒk#,5?P6Q^['E )Ò*PdRR9fK[Iԭld122qV\i{xƯdd}b*ʳrc$8 )Wyu(ഓѺbTBxHŨYxq=hi r$p1h;DdOӏEP,%_>dK!B!*Z2PJWÇ-d鵹N׋Ӆ>_~ [\u]ٝF]ݨ{[Z?RU`Ji˓ \h<ækR^i "{YTo#F-N\}DhHPS, UثWb]y65⫖t7쟗/lLO.@HX<îzďk (KE He}ݷ',!({˟4Kwvw6Fy4wCgE N"{KS+GK$ai\fGq 审min+oCe0BĒdeIx:'ܗ%iJmhk64ctz~$?|AUo]uBM.+~l,Xq<9A3FFܨ(y̺}"Zz4ǒ4YLcIf8#$;(!tk!U is$)h`_.L-&7^tvOfT i,1@n&ȉz5M\yvA{+J.[[r*2]+'r a[H{F.mbc4o#qt~.%!GKӯ5;=L+IŔvDl{E#}|TqM!͝٧hl3!=(86z'/0@>OZ+kU`K5WiwIcsj 9¿k+$1H,46lR;lw{[DBqh%d$W"/ycQ \[Uc$@0cxe+$Z>ot;i;I!-!Szl&NO`RM~\yUPγjW~2,Aynmokp/#YmyW3T-o>%,Xޥc{jQ{gH?-&^EVv-c-.٤s=0["?# CX-{ca}{Yh~`@~Q+,^oi nV[ ][*4=UJ(ZHW͉6 0t^N2J"0lQ,Q/]k ymZX䴵d- $zX[IG*QI$73꿣LR]TiVeJ8Mr:Vi, 7ɺ_^Iq aRAB*$&YoW,J$qUu(o5zxu=^][TRSX(olxXϏ/˓ wImj[:}R,( /%+Haw冫7ZI%vqo=Rc2O,9RUgq2h,o,n.i=Kx/ JhޑRޚzd>) +LZ֝ocqh, ROܼo,zN4+ۚ?`Tވ'9Io. W5'[8!W|>"8PzO埘co!`fmkgwmE=Bq,8.-)3Ce{k:H,dNimEVkFwDȧz'M]C(KoH=ƣ;"ax1H̼⿴;q5ݍBݼV8YZO Y lb~o#rGyaZ~ Gwd& NEݹJg v*UثWb]v*UثWb]v*UثWb]v*UثWb^}M ?~쟗/lLO.@_YrD&xP\4>ZxѽHkIlmwg&݌oH̢~\y6KolcxRn,d!T&8V:K V[ISx+r y_DeOEcK{a.c xzM+ȕ+~YIEn/gu`[r~6*@ѸrߞLE2)0zɌ?VO?'%)=Ǔ|qgdyKu!r%Pܞ>~⫇|zva(#TH<*4DTHQ8Ã|yꖦf14VYV:z'.-/ň;$yfI%іif7<3 8jIUrΟb쟗/lLO.@kŮjJma$@)!CڬIG`UIR/lO\oδos\x?k EL+TZo/zßIÕ.4ŰY*_o`XR?U#i]0W*'K&ֽ?2h~es{Ti` orx>JW}/WR˗ :Pqz8q/JWb^}M ?~쟗/lLO.@叞bԷjkwPzy)%,J>-9g)iiZ]qЙV}B9`1-Te E{.B>kI[KսH0u0sK'_Wxཕd qimmm-q麅RkHח?$NSOOaхB[AukB\Kx9s ~~[yGЭtkycafK=Sx][(žkvbmS&<nm~[۟*L\XPĵ-瓣pg2^mw&[s{ZDFFCFga5~2EFa%_5kKWtZY1ex%n_e:/R/ҮZd?Ɠ-OwIPߺjv7BؔyI%r_}b5&?҄lӦ3Eçm"K+Zѭ#>rxn%w._j?q ODyYZ,Vm :O$_He)+E/ Q>-@K o!kPt/JZ bwm ڪkwWrLuE!nOXMyc46Ho^TԬgy67'ӗȉiv=j>_ia5c[H-KQ(N+;+[OM3EBɺiP] tm#Մ-1 F]eg)lLZ@YySڞ=IeQXr ;iSoEE4f\Bd4S<ץj7 jԵ~Jc6P_^M/,&I-跥/0q y4{m _V"}VOJ?kg Fq3\Lg*nt~Q/)1hoD$?%yĹIb@-.#-\7nU 醐?I|$r|c)KW~5y_h=&hŰڌp(~20]Hu+Hˉ|5摣>4u0Z?,x/<{~;֒n~"v?JKu4f'Xۗ!BrrV٤īzӮ<憱#ԿBvWuCҚ%=9>)|>Tnj}IJE*5p+;JsEf~wmcR7 ~%a61Ȗւ;ߔ>cDzF?[#$&:7E!n c6M1~g詥XJbEiD!&997Y fi&i绕ոhbN*4[ jJ<*d=?4^eѡvQZ,l!I |\y2"R]{"[{X+DI',qȿq\hhdhf`Zބ_NPLR"+q|,"cImk^ҭa[DvYeg6DKl@c'4OPn[־$XaӮI8F;/rrbsZ&'BJXѧ  KŖX#=X>~5'm:|ZՌw-W)Aoo1z^9~||"!kk.0[Y.L-PiG,dicToM;qǀ|o.QVhl"7!>KK>2aAmyF.fIk->]VHBBYݽ' ȿV⾳R;G59d[K<燻M7<' =梱 ""77~AM=a ZQӜK̑ns?/O}7jVe,K_OP8 =P:Ē,KI>,M?RDܖ\a}v{~%}b9#9~>[Kk(G}jY.,կKh&G,b>ErL1%vK󎂰_A5fK4rYG3+IB[?EHK-.4{Xǭpo@<+/#gK +q,q4Rz8h$fXFNkˋᕵyi$SHVfycV\ʬ38V)hGmI3t$ Od#\IVdF NqWYm ȜIH`QQ] ]v*UثWbTiIZ`.H4n,~bWb]v*UثWb>UrΟb쟗/lLO.@Zis)m#,D_ye>skǥO,$ (e x/,Rމ{u5ʾU-)T4*QrN\B&Vyz fKDO= KesuC+RHӏ'9`ԅߗ_\M坛2"$Wp߶^_WJ-U:\v ,8@yD!UEehY]M%-e5svsk+~'9I^_:/4)l%&;7)pe)Gì\X2۲[8.i c9=_Q?cZJ ڜm=:%͕2#iK]Q6ZN_A$~]yp,3]?܁]וu܅G֯gj*GZ1 [z-f fsKCMS]j qC@/>w׵oVw{sHNGu~:EΝ _;~kϫs[i%҉$qBݬYiKYdf<mC^b%\K[keϧ]Cz"#h{e()5o,vZ %ԧRIGCQw0WGi/FRy6e'S\\%Q%=:zN:G/4[lyn'^%G ˧MGԡJ&8kdG"^<^;@qN%M48kZh΃;i_Zx} DQZ&HS=鴳MËK4M-'-=Wc\#ʟU_ahkk, h経4׳N^P#7B/u4 c(xEKkpꎈGq3˅ğ\ M]@Ow>NV"=ìޣ6 9#q"E9a:O+Mh YOMu )ӗjjzoZ]͓Rs4GP *5mG6asHmxEN'fH=2*+qz~C#O'i Hź#VlˋMF;(̗2۲ZFG`Uo_UKtͭJOhpג4rP%_Z[#-SG5dOQXzS}\'!;1EQ4kJZizv*U}j +Ȣx"x#+:ͣ&ˍ#v*UثU#m%G bWb]J΋6USgYT >\E눝=u~ 7JZO˱޶]&KIv<8˿_)i?6?.LJzwrk-'Fe[.Mԥ}eoɯcÏlM95R#cxq&Rl]>7JZO˱޶]&KIv<8˿_)i?6?.LJzwrk-'Fe[.Mԥ}eoɯcÏlM95R#cxq&Rl]>7JZO˱޶]&KIv<8˿_)i?6?.LJzwrk-'Fe[.Mԥ}eoɯcÏlM95R#cxq&Rl]>7JZO˱޶]&KIv<8˿_)i?6?.LJzwrk-'Fe[.Mԥ}eoɯcÏlM95R#cxq&Rl]>7JZO˱޶]&KIv<8˿_)i?6?.LJzwrk-'Fe[.Mԥ}e~^ߤ?E?ާ.~>3E}">k_*zDo/A%gNT%m2Gn߳܀vO:/j#-s6pmWq?9V6d nͫU\xt_fտ .<Bۿ:/j!mYojK΋,ڷ_%ǀ[wEm[گ-s6pmWq?9V6d nͫU\xt_fտ .<Bۿ:/j!mYojK΋,ڷ_%ǀ[wEm[گ-s6pmWq?9V6d nͫU\xt_fտ .<Bۿ:/j!mYojK΋,ڷ_%ǀ[wEm[گ-s6pmWq?9V6d nͫU\xt_fտ .<Bۿ:/j!mYojK΋,ڷ_%ǀ[wEm[گ-s6pmWq?9V6d nͫU\xt_fտ .<Bۿ:/j!mYojK΋,ڷ_%ǀ[wEm[گ-s6pmWq?9V6d nͫU\xt_fտ .<B[8z~9 z4s9}/?ypEDd`'<P  3 3"`'88j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH V`V FNormald(CJOJPJQJ^J_HaJmH sH tH Z`Z F Heading 1$<@&5CJ KH OJPJQJ\aJ DA`D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List V/V FHeading 1 Char"5CJ KH OJPJQJ\^JaJ 4U`4 F0 Hyperlink >*ph*W`* F`Strong5\.X`!. F@Emphasis6]D@2D F List Paragraph ^m$PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] ]c.+@ITfg3579;B 3N]_g468:<=`c&_'f'l'''34!4a4445<6E6VOOOP QQ]XXXXXXXXXXl,R$.n|d 4@z(  B  AZ?Z*image_gallery?img_id=1531757&t=1267644981866Picture 2image_gallery?img_id=1531757&t=1267644981866yK yK http://www.consultantlive.com/image/image_gallery?img_id=1531757&t=1267644981866yX;H,]ą'c3"B S  ?TO]6!\figure1case1case2case3table2 '6VO] '6VO]CJ{LZMOJTu z!!""""(((((((), ,,',,,--.%.2.9.+/;/E/O/k1r12(2)2428!8,8/8889999::::*:,:-:/:L:V:W:j:;;;;;;;;<<V=Y=^=a=b=p={====BB4D=DEGMGRG[GGGGG5H>HJIQIJJFJVJZJ_JJJJJKKKKLLLLM!MqMxMMMMMANONiNyNNNNNTOUO3R6R7RBRMRPRQR^R`RcRdRrRRRRRRRRSS S(T+T3T8TTTeWhWWWXXKXNXbXeXfXpX}XXXXXXXXEYLY] EL.0 !''^4`466778#8%:/:;;BBFDIDEEKKLL.M3M9Nxh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hH1T         Y%U5[pWF"G]]@pp-/9;<(W]x@xx@@x6xt@xDxHx@x@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.{ @Calibri7K@Cambria?= * Courier New;WingdingsA BCambria Math"1h`&d& O/ O/Y88n0`]`]2qHX $PF2!xxJanetJanet Oh+'0 px  JanetNormalJanet1Microsoft Office Word@ @@): O՜.+,D՜.+,, hp|  /`]  Title  8@ _PID_HLINKSA Bdhttp://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=6table2_Qhttp://www.consultantlive.com/image/image_gallery?img_id=1531757&t=1267644981866x ";Ihttp://www.consultantlive.com/display/article/10162/1531922?pageNumber=1figure1ACIhttp://www.consultantlive.com/display/article/10162/1531922?pageNumber=4case3 dhttp://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=4table1AD Ihttp://www.consultantlive.com/display/article/10162/1531922?pageNumber=3case2AE Ihttp://www.consultantlive.com/display/article/10162/1531922?pageNumber=2case1Hdhttp://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=2figure2v5dhttp://www.consultantlive.com/gastrointestinal-disorders/content/article/10162/1531922?pageNumber=2case1/-<http://www.consultantlive.com/display/article/10162/1531922x _Qhttp://www.consultantlive.com/image/image_gallery?img_id=1531757&t=1267644981866x   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry F=Data 1Table)WordDocumentKSummaryInformation(DocumentSummaryInformation8CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q